Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Gross Margin (2016 - 2025)

Immucell (ICCC) has disclosed Gross Margin for 16 consecutive years, with 42.92% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin rose 1398.0% year-over-year to 42.92%, compared with a TTM value of 40.93% through Sep 2025, up 1367.0%, and an annual FY2024 reading of 29.97%, up 783.0% over the prior year.
  • Gross Margin was 42.92% for Q3 2025 at Immucell, down from 43.72% in the prior quarter.
  • Across five years, Gross Margin topped out at 51.72% in Q1 2022 and bottomed at 8.73% in Q1 2023.
  • Average Gross Margin over 5 years is 35.89%, with a median of 38.75% recorded in 2021.
  • The sharpest move saw Gross Margin crashed -4300bps in 2023, then surged 2325bps in 2025.
  • Year by year, Gross Margin stood at 47.04% in 2021, then crashed by -46bps to 25.37% in 2022, then dropped by -7bps to 23.48% in 2023, then soared by 56bps to 36.53% in 2024, then increased by 17bps to 42.92% in 2025.
  • Business Quant data shows Gross Margin for ICCC at 42.92% in Q3 2025, 43.72% in Q2 2025, and 41.58% in Q1 2025.